Brown Wealth Management LLC increased its stake in CVS Health Corporation (NYSE:CVS – Free Report) by 239.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,306 shares of the pharmacy operator’s stock after acquiring an additional 8,677 shares during the period. Brown Wealth Management LLC’s holdings in CVS Health were worth $977,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd grew its position in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 281 shares in the last quarter. Ares Financial Consulting LLC purchased a new position in CVS Health in the fourth quarter worth about $29,000. Dogwood Wealth Management LLC boosted its position in shares of CVS Health by 93.7% during the fourth quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator’s stock valued at $29,000 after buying an additional 179 shares during the period. GoalVest Advisory LLC purchased a new position in shares of CVS Health during the fourth quarter valued at approximately $32,000. Finally, Financial Consulate Inc. boosted its position in shares of CVS Health by 99.6% during the fourth quarter. Financial Consulate Inc. now owns 499 shares of the pharmacy operator’s stock valued at $40,000 after buying an additional 249 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.
Wall Street Analyst Weigh In
Several research analysts have issued reports on the company. Morgan Stanley boosted their target price on CVS Health from $93.00 to $106.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. HSBC boosted their target price on CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Tuesday, May 5th. Truist Financial boosted their target price on CVS Health from $98.00 to $102.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Barclays boosted their target price on CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of CVS Health in a research report on Friday, May 8th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $98.08.
Insider Buying and Selling
In related news, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.85% of the stock is owned by company insiders.
CVS Health Stock Down 1.9%
Shares of NYSE CVS opened at $94.18 on Wednesday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The firm has a market capitalization of $120.16 billion, a price-to-earnings ratio of 41.49, a PEG ratio of 0.94 and a beta of 0.60. The stock has a 50 day moving average price of $79.39 and a 200 day moving average price of $78.76. CVS Health Corporation has a 52-week low of $58.50 and a 52-week high of $98.43.
CVS Health (NYSE:CVS – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.CVS Health’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Sell-side analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current year.
CVS Health Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were paid a $0.665 dividend. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.8%. CVS Health’s payout ratio is 117.18%.
More CVS Health News
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: CVS Health and WGU launched an online pre-pharmacy degree program aimed at building a pipeline of future pharmacists nationwide, which could help address labor shortages and support CVS’s retail pharmacy operations. CVS Health(R) and WGU Launch Online Pre-Pharmacy Degree Program for Future Pharmacists Nationwide
- Positive Sentiment: CVS also backed EnsembleIQ’s campaign supporting retail pharmacy as a way to help fill healthcare gaps, reinforcing CVS’s role in community pharmacy and care access. EnsembleIQ’s DSN, a Trusted Source in the Community Pharmacy Space, Launches Campaign in Support of Retail Pharmacy Filling Health Care Gaps
- Positive Sentiment: CVS Health published a study showing many Medicare members struggle with digital health literacy, which supports the company’s push to invest in digital tools and member engagement. CVS Health study reveals a need for greater digital health literacy for Medicare members
About CVS Health
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
Further Reading
- Five stocks we like better than CVS Health
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
